• Neurocrine Biosciences will present tardive dyskinesia research Nov. 7, 2026, at the NEI Fall Congress in Colorado Springs.
• KINECT-PRO analyses show valbenazine improved the condition’s socio-emotional and physical impacts; separate analyses examine symptomatic remission across two clinical trials.
• A PET study in healthy male adults found once-daily valbenazine provided greater, more predictable exposure than extended-release deutetrabenazine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611031605PR_NEWS_USPR_____LA87999) on November 03, 2026, and is solely responsible for the information contained therein.